1. Home
  2. Database Cancer Drugs

Database cancer drugs

CancerDrugs_DB is a curated listing of licensed cancer drugs produced by the Anticancer Fund. Source data comes from the NCI, FDA, EMA and other data sources. The intention is to provide researchers, clinicians and regulators with an easily filtered database of licensed drugs used in the treatment of cancer. Drugs which are used in cancer treatments to alleviate symptoms or other supportive care uses or which are used for diagnostic purposes are not included. Investigational agents and experimental treatments being used in clinical trials are also not included.

Cite as: Pan Pantziarka, Rica Capistrano I, Arno De Potter, Liese Vandeborne, Gauthier Bouche (2021). An Open Access Database of Licensed Cancer Drugs Frontiers in Pharmacology, 11 March 2021 DOI: 10.3389/fphar.2021.627574

A machine-readable version of this database can be downloaded here: cancerdrugsdb.txt. The ReDO database of repurposing candidates in oncology can be accessed here: ReDO_DB.

Summary results as of last build on: 28/11/24NumberPercentage
Number of licensed anticancer drugs321
FDA approved anticancer drugs29090.34%
EMA approved anticancer drugs21566.98%
Euro nationally approved anticancer drugs5015.58%
Non-FDA/EMA/European113.43%
Drugs included in WHO EML5416.82%
Single API drugs31798.75%
Combination (>1 API) drugs41.25%


Click in header cell to sort table by that column. Hover over header cell for additional text.

Database build date: 28/11/24

Number of drugs in database: 321 (Filter not active)


Product EMA FDA EN Other WHO Year Generic DrugBank ID ATC ChEMBL Indications Targets Last Update
Abemaciclib Y Y N N 2017 N DB12001 L01EF03 CHEMBL3301610 Advanced Breast Cancer; Metastatic Breast Cancer CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA 2024-07-24
Abiraterone Y Y N Y 2011 Y DB05812 L02BX03 CHEMBL254328 Metastatic Castration Resistant Prostate Cancer CYP17A1; CPB2; AR; YBX1; TP53; PTEN; SRD5A2; APC; SRD5A1; TSPYL1; SRD5A3; DSE 2024-07-25
Acalabrutinib Y Y N N 2017 N DB11703 L01EL02 CHEMBL3707348 Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2 2024-07-24
Aclarubicin N N N Japan N DB11617 L01DB04 CHEMBL502620 TOP2A; SMN1; CSF2 2024-07-24
Adagrasib N Y N N 2022 N DB15568 L01XX77 CHEMBL4594350 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer KRAS; GPM6B 2024-07-24
Afamitresgene Autoleucel N Y N N 2024 DB18592 CHEMBL4802254 Unresectable or metastatic synovial sarcoma 2024-10-30
Afatinib Y Y N Y 2013 N DB08916 L01EB03 CHEMBL1173655 Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO 2024-07-24
Aflibercept Y Y N N 2011 N DB08885 S01LA05; L01XX44 CHEMBL1742982 Metastatic Colorectal Cancer (MCRC) VEGFA; PIGF; VEGFC; VEGFB; PGF 2024-07-24
Aldesleukin N Y Y N 1992 N DB00041 L03AC01 CHEMBL1201438 High Risk Neuroblastoma; Metastatic Melanoma; Metastatic Renal Cell Carcinoma IL2RA; IL2RB; IL2RG 2024-07-24
Alectinib Y Y N N 2015 N DB11363 L01ED03 CHEMBL1738797 Refractory, metastatic Non small cell lung cancer RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF 2024-07-24
Alemtuzumab Y Y N N 2001 N DB00087 L04AA34 CHEMBL1201587 B-Cell Chronic Lymphocytic Leukemia; T-Cell Prolymphocytic Leukemia CD52; TP53; CXCL12 2024-02-07
Alitretinoin Y Y N N 1999 N DB00523 D11AH04; L01XF02 CHEMBL705 AIDS-related Kaposi's Sarcoma RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR 2024-07-24
Alpelisib Y Y N N 2019 N DB12015 L01EM03 CHEMBL2396661 Advanced Metastatic Breast Cancer F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS 2024-07-24
Altretamine N N Y N 1990 N DB00488 L01XX03 CHEMBL1455 Ovarian Cancer; Ovarian Cancer Stage III CYP1A2 2024-02-07
Aminolevulinic Acid Y Y N N 1999 N DB00855 L01XD04 CHEMBL601 Basal Cell Carcinoma (BCC); Squamous Cell Carcinoma (SCC) BCL2 2024-02-07
Amivantamab Y Y N N 2021 N DB16695 L01FX18 CHEMBL4297774 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer DRD4; DXO 2024-07-24
Amrubicin N N N Japan N 2002 DB06263 L01DB10 CHEMBL1186894 TOP2A 2024-02-07
Amsacrine N N N N 1987 N DB00276 L01XX01 CHEMBL43 Leukemia, Acute; Refractory Leukemia TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2 2024-07-24
Anastrozole N Y Y Y 1995 Y DB01217 L02BG03 CHEMBL1399 Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD 2024-07-24
Apalutamide Y Y N N 2018 N DB11901 L02BB05 CHEMBL3183409 Nonmetastatic Prostate Cancer AR; BEVI 2024-07-24
Arsenic Trioxide Y Y N Y 2018 Y DB01169 L01XX27 CHEMBL1200978 Refractory Acute Promyelocytic Leukemia RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1 2024-07-25
Asciminib Y Y N N 2021 N DB12597 L01EA06 CHEMBL4208229 Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase ABL1; BCR 2024-07-24
Asparaginase Y Y N Y 1994 N DB00023 L01XX02 CHEMBL2108989 Acute Lymphoblastic Leukaemias (ALL) ASNS; PYGL; MYBBP1A; PNPLA3; MTHFR; LPL; MIR4268; GATA3; ATF5; HLA-DRB1; GRIA1; MIR3117; TYMSOS; ETV6; CPA2; NFATC2; TYMS; SOD2 2024-07-24
Atezolizumab Y Y N N 2016 N DB11595 L01FF05 CHEMBL3707227 Metastatic Non-Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Triple Negative Breast Cancer (TNBC); Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma CD274 2024-07-24
Avapritinib Y Y N N 2020 N DB15233 L01EX18 CHEMBL4204794 Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor KIT; PDGFRA; FLT3; DPT; CBL 2024-07-24
Avelumab Y Y N N 2017 N DB11945 L01FF04 CHEMBL3833373 Locally advanced disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic Merkel Cell Carcinoma (MCC); Metastatic disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC) CD274; PMS2; MSH2; MSH6; MLH1; STK11; ATM 2024-07-24
Axicabtagene Ciloleucel Y Y N N 2017 N DB13915 L01XX70 CHEMBL3989989 Refractory Diffuse large B-cell lymphoma NOS; Refractory High grade B-cell lymphoma Burkitt-like lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Relapsed Diffuse large B-cell lymphoma NOS; Relapsed High grade B-cell lymphoma Burkitt-like lymphoma; Relapsed Primary Mediastinal Large B-Cell Lymphoma CD19 2024-02-07
Axitinib Y Y N N 2012 N DB06626 L01EK01 CHEMBL1289926 Advanced Thyroid cancer KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4 2024-07-24
Azacitidine Y Y N N 2004 Y DB00928 L01BC07 CHEMBL1489 Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia NRAS; DNMT1; TG; MTHFR; ALDH1A1; GMNN; NFE2L2; IDH1; SMAD3; XRCC1; KRAS; TAGLN; FLT3; ATAD5; AFP; GGT1; MYC; ABL1; CDA; MGMT; TP53; AR; IDH2; NR3C1; THPO; LIF; HTT; PLAU; PTPN11; DNMT3A; TYMS; CBL; HBB; GSTP1; CD247; RORC; TRIT1; GATA2; TET2; IL11 2024-07-25
BCG Vaccine Y Y N Y N DB12768 L03AX03 CHEMBL2108905 Non-Invasive Bladder Urothelial Carcinoma; Recurrent Superficial Bladder Cancer; Urothelial Carcinoma Recurrent; Carcinoma in situ of urinary bladder KLK3; IL2; PIK3CB 2024-07-25
Belantamab Mafodotin Y Y N N 2020 N DB15719 L01FX15 CHEMBL4298209 Relapsed Or Refractory Multiple Myeloma ECE1; TUBB; TUBB4A; TUBA1B; TUBA3E; TUBA1C; TUBB2A; TNFRSF17; TUBB2B; TUBB8; TUBA3C; TUBB6; TUBB4B; TUBB3; TUBA4A; TUBA1A; TUBB1 2024-07-24
Belinostat N Y N N 2014 N DB05015 L01XH04 CHEMBL408513 Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2 2024-07-24
Belotecan N N N South Korea N 2003 DB12459 L01CE04 CHEMBL2111084 TOP1 2024-02-07
Belzutifan N Y N N 2023 N DB15463 L01XX74 CHEMBL4585668 Advanced Renal Cell Carcinoma HMGB2 2024-07-24
Bendamustine N Y Y Y 2008 Y DB06769 L01AA09 CHEMBL487253 Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma ATM; TP53; CD69 2024-07-24
Bevacizumab Y Y N Y 2004 N DB00112 S01LA08; L01FG01 CHEMBL1201583 Cervical Cancer Metastatic; Metastatic Colorectal Cancer (MCRC); Metastatic Non-Squamous Non-Small Cell Lung Cancer; Metastatic Renal Cell Carcinoma; Persistent Cervical Cancer; Recurrent Cervical Cancer; Recurrent Glioblastoma; Stage III epithelial ovarian cancer following initial surgical resection; Stage IV epithelial ovarian cancer following initial surgical resection; Fallopian tube cancer following initial surgical resection; Locally advanced nonsquamous non-small cell lung cancer; Primary peritoneal cancer following initial surgical resection; Recurrent Non-Squamous Non-Small Cell Lung Cancer; Recurrent Platinum-Sensitive Epithelial Ovarian Cancer; Recurrent Platinum-resistant Epithelial Ovarian Cancer; Recurrent platinum drug resistant Fallopian tube cancer; Recurrent platinum drug resistant primary peritoneal cancer; Recurrent platinum sensitive primary peritoneal cancer; Recurrent platinum-sensitive fallopian tube cancer; Unresectable Non-Squamous Non-Small-Cell Lung Cancer VHL; CCT3; BRAF; VEGFA; NF2; SLC19A1; SHMT1; HSP90AB1; NF1; GC; KRAS; MMP2; EDN1; ARID1A; MGAT4A; HOXC10; KIT; EGFR; CXCL8; TP53; RALBP1; VEGFB; FOXF1; CSPG4; VEGFC; ANXA11; F2R; EML4; CXCR4; GGH; CD274; PDGFRB; PRKCA; MMP9; ALK; CXCR2; HRAS; PIK3CA; THBS2; IDH1 2024-07-24
Bexarotene Y Y N N 1999 Y DB00307 L01XF03 CHEMBL1023 Refractory peripheral cutaneous T-cell lymphoma NR1I2; OPN1SW; RXRB; RXRG; USP1; HCN2; NR1H3; RXRA; MAPK8; KAT2A; BLM; CCND1 2024-07-24
Bicalutamide N Y Y Y 1995 Y DB01128 L02BB03 CHEMBL409 Stage D2 Prostatic carcinoma CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI 2024-07-25
Binimetinib Y Y N N 2018 N DB11967 L01EE03 CHEMBL3187723 Metastatic Melanoma; Unresectable Melanoma BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5 2024-07-24
Bleomycin N Y Y Y 1973 Y DB00290 L01DC01 CHEMBL403664 Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP 2024-07-24
Blinatumomab Y Y N N 2014 N DB09052 L01FX07 CHEMBL1742992 Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory; Relapsed B cell precursor Acute lymphoblastic leukemia CD3E; CD19; KMT2A; BCR; CD3D; ABL1; GLRA2; CD247; GMFB; CD3G 2024-07-24
Bortezomib Y Y N Y 2003 Y DB00188 L01XG01 CHEMBL325041 Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM) PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3 2024-07-25
Bosutinib Y Y N N 2010 N DB06616 L01EA04 CHEMBL288441 Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1 2024-07-24
Brentuximab vedotin Y Y N N 2011 N DB08870 L01FX05 CHEMBL1742994 B-large cell anaplastic Lymphoma (Kiel Classification) refractory; Refractory Hodgkin Lymphoma; Post-autologous hematopoietic stem cell transplantation Hodgkin lymphoma TNFRSF8; ALK; TUBA1C; TUBB4B; TUBB3; TUBA3C; TUBB2A; TUBA1A; TUBB8; TUBB2B; TUBA3E; TUBA4A; E4F1; TUBB; TUBA1B; TUBB4A; TUBB1; TUBB6 2024-07-24
Brexucabtagene Autoleucel Y Y N N 2020 N DB15699 L01XL06 CHEMBL4594618 Refractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma CD19 2024-02-07
Brigatinib Y Y N N 2017 N DB12267 L01ED04 CHEMBL3545311 Metastatic Non-Small Cell Lung Cancer ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1 2024-07-24
Buserelin N N Y N 2017 N DB06719 L02AE01 CHEMBL2110824 Stage D2 Prostatic carcinoma GNRHR; IGFBP1 2024-02-07
Busulfan Y Y N N 1954 Y DB01008 L01AB01 CHEMBL820 Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia GSTA1; ADK; ABL1; CYP2C19; ABCC3; MTHFR; THPO; ITGAL; BCR; CYP1A2; GALC; GSTM1; CYP2B6; G6PD; CYP2D6; CYP3A4; GSTP1; CYP2C9; SHBG 2024-07-25
Cabazitaxel Y Y N N 2010 N DB06772 L01CD04 CHEMBL1201748 Refractory, metastatic hormone-refractory Prostate cancer TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5 2024-07-24
Cabozantinib Y Y N N 2012 N DB08875 L01EX07 CHEMBL2105717 Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET 2024-07-24
Calaspargase Pegol N Y N N 2018 N DB14730 L01XX86 CHEMBL2108728 Acute Lymphoblastic Leukaemias (ALL) ASRGL1 2024-02-07
Capecitabine Y Y N Y 1998 Y DB01101 L01BC06 CHEMBL1773 Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7 2024-07-25
Capivasertib Y Y N N 2023 N DB12218 L01EX27 CHEMBL2325741 Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1 2024-07-24
Capmatinib Y Y N N 2020 N DB11791 L01EX17 CHEMBL3188267 Metastatic Non-Small Cell Lung Cancer DRD4; MET; PTEN 2024-07-24
Carboplatin N Y Y Y 1989 Y DB00958 L01XA02 CHEMBL1351 Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1 2024-07-24
Carfilzomib Y Y N N 2009 N DB08889 L01XG02 CHEMBL451887 Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM) PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5 2024-07-24
Carmofur N N N Japan N DB09010 L01BC04 CHEMBL460499 CYP3A4 2024-02-07
Carmustine Y Y N N 1977 Y DB00262 L01AD01 CHEMBL513 Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma MGMT; ALDH1A1; GSR; CYP2C19; CYP2D6; CYP2C9; PLAU; CYP1A2; G6PD; E2F1; CYP3A4 2024-07-25
Cemiplimab Y Y N N 2018 N DB14707 L01FF06 CHEMBL4297723 Metastatic cutaneous squamous cell carcinoma; Locally advanced cutaneous squamous cell carcinoma, and not a candidate for curative surgery or curative radiation PDCD1; CD274; EGFR; GM2A; ALK; CDK12; ROS1 2024-07-24
Ceritinib Y Y N N 2014 N DB09063 L01ED02 CHEMBL2403108 Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR 2024-07-24
Cetuximab Y Y N N 2004 N DB00002 L01FE01 CHEMBL1201577 Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN); Metastatic Colorectal Cancer (MCRC); Metastatic Squamous Cell Carcinoma of the Head and Neck; Recurrent Squamous Cell Carcinoma of the Head or Neck; Regionally Advanced Squamous Cell Carcinoma of the Head and Neck NRAS; TGFA; EGFR; EREG; CTNNB1; KRAS; CXCL8; BRAF; NT5E; BDNF; PIK3CA; EGF; NF2; PTEN; CDKN2A; MGAT4A; BAX; BTC; SMAD4; NRG2; NRG3; ERBB2; HRAS; ERBB3; FCGR3A; VPS37A; AREG; DXO; PTP4A3; MET; HBEGF; TP53; MAP2K1; IDH1; NRG1; GC 2024-07-24
Chlorambucil N Y Y Y 1957 N DB00291 L01AA02 CHEMBL515 Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12 2024-07-24
Ciltacabtagene Autoleucel Y Y N N 2022 N DB16738 CHEMBL4802263 Refractory Multiple Myeloma, Relapsed Multiple Myeloma 2024-07-24
Cisplatin N Y Y Y 1978 Y DB00515 L01XA01 CHEMBL2068237 Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma CSNK2A3; HEXB; ATM; MLLT3; PPP1R13L; PIK3CA; ERCC4; PLAU; DCBLD1; HMGB1; TPMT; TP53; ERCC1; SYNE3; MECP2; FXN; FGFR1; BAX; ATR; ANPEP; CLCN6; BRCA1; CBX1; BCL2; FANCC; GRP; ERCC6; DFFB; GALNT14; IL6; PRL; GPX5; HPGD; GNAS; TGM2; DDIT3; MGMT; ESR1; MDH2; FASLG; NFE2L2; MPHOSPH8; KDM4E; XIAP; MUTYH; CASP3; CGA; XRCC1; RGS4; TERC; ABCC1; G6PD; CDC25C; GADD45A; ERCC2; FAS; TOP1; KRAS; GSTP1; GSTT1; ATRX; GABPA; GCLM; GCLC; ABCC4; SLC19A1; TYMS; HSD17B10; CYBA; ASS1; LIF; AURKA; ALDH1A1; MTHFD1; FANCA; POLR1G; CD44; MAPT; ALK; ATP7B; EGFR; RB1; SLC22A1; H2AC25; NRAS; APEX1; RECQL; GSTM4; NF2; PPARD; TMEM43; STAT1; OSGEP; GALNT18; DNMT1; BIRC7; MT1H; NR1I2; MAP3K1; RARS1; NHLH1; BRCA2; MDM2; MIR21; EHMT2; IDH1; XRCC3; TP73; SMARCA4; MYCN; CCND1; UBE2I; RAF1; ADH1C; ALOX15; DRAM1; AQP9; HSPA8; ACTL6A; IFNG; E2F1; SEMA6A; KRT20; CDH17; HTR4; MT1F; WFS1; BIRC5; NRG1; RRM1; CHEK1; ABCC5; HSPA4; MSH2; ACSS2; BLMH; CDK12; KAT2A; XRCC5; PTEN; CXCR4; NTRK2; FGFR3; MYC; CD274 2024-07-25
Cladribine Y Y N N 1993 Y DB00242 L04AA40; L01BB04 CHEMBL1619 Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL) DCK; TP53; XIAP; RRM2B; TGFB1; BCL2L2; RRM1; RRM2; CDKN1A; DIABLO; ADA; YES1; IL2RA; NT5C1A; NFE2L2 2024-07-24
Clofarabine Y Y N N 2004 Y DB00631 L01BB06 CHEMBL1750 Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis RRM2; AR; POLA1; POLD2; POLA2; FLT3; POLE2; PRIM1; NIPSNAP2; POLD1; APBB1; GBA1LP; RRM2B; POLD3; POLE3; POLE; PRIM2; POLD4; RRM1 2024-07-24
Cobimetinib Y Y N N 2015 N DB05239 L01EE02 CHEMBL2146883 Metastatic Melanoma; Unresectable Melanoma BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF 2024-07-24
Copanlisib N Y N N 2017 N DB12483 L01EM02 CHEMBL3218576 Relapsed Follicular Lymphoma PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B 2024-07-24
Crizotinib Y Y N N 2011 N DB08865 L01ED01 CHEMBL601719 Metastatic Non-Small Cell Lung Cancer ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR 2024-07-24
Cyclophosphamide N Y Y Y 1959 Y DB00531 L01AA01 CHEMBL88 Acute Lymphoblastic Leukaemias (ALL); Acute Myelocytic Leukemia; Adenocarcinoma of the Ovaries; Breast Cancer; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia (CLL); Chronic Myeloid Leukemia (CML); Disseminated Neuroblastoma; Ewing's Sarcoma; Lung Cancers; Lymphoma, Hodgkins; Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Waldenstrom's Macroglobulinemia (WM); Advanced Alibert-Bazin syndrome; Histiocytic lymphoma; Metastatic gestational trophoblastic tumor; Mixed-cell type lymphoma; Refractory Small cell lung cancer; Relapsed Wilm's tumor EHMT2 2024-07-25
Cytarabine Y Y N Y 1969 Y DB00987 L01BC01 CHEMBL803 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia ADH1A; IDH2; TP53; CYP3A4; GSTP1; PRIM1; IKZF1; POLA1; HSPA4; KIT; ITGAV; POLD2; GATA3; CCND1; SULT2B1; NQO1; WT1; P2RY12; MSH2; IL1B; EHMT2; TYMSOS; CPT1A; MIR4268; ALK; IGHMBP2; IDH1; CSF2; KMT2A; POLE; NOS3; BIRC5; PRIM2; DOK5; ABCC3; RRM1; CYP2D6; quinone dehydrogenase 2; BMP7; FLT3; TYMS; ATF5; PNPLA3; SLC22A12; NT5C2; POLE2; NRG1; FCGR3A; BRD10; CYP2C9; MIR3117; POLD3; POLA2; SLC29A1; CYP1A2; UGT1A1; VDR; ABCC4; NRAS; RUNX1; RRM2B; POLE3; SLCO1B1; TP73; MED12L; XIAP; FCGR3B; CYP2E1; TPMT; POLD4; NTRK1; CBR3; POLB; MAGEA1; POLD1; NT5C3A; CYP2C19; RRM2; CDA; NCOA3; LINC00251 2024-07-24
Dabrafenib Y Y N N 2013 N DB08912 L01EC02 CHEMBL2028663 Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2 2024-07-24
Dacarbazine N Y Y Y 1975 Y DB00851 L01AX04 CHEMBL476 Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor ADK; CYP2C19; CYP1A2; CYP2D6; FN1; CYP2C9; POLA2; MGMT; BAX; CYP1A1; CYP3A4; GSTM1; EPM2AIP1; CXCL8; PLAU 2024-07-25
Dacomitinib Y Y N N 2018 N DB11963 L01EB07 CHEMBL2110732 Metastatic Non-Small Cell Lung Cancer ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2 2024-07-24
Dactinomycin N Y N Y 1964 Y DB00970 L01DA01 CHEMBL1554 Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT 2024-07-24
Daratumumab Y Y N N 2015 N DB09331 L01FC01 CHEMBL1743007 Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma 2024-07-24
Daratumumab, Hyaluronidase N Y N N 2020 N DB09331 L01FC01 CHEMBL1743007 Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma 2024-07-24
Darolutamide Y Y N N 2019 N DB12941 L02BB06 CHEMBL4297185 Non-mestatatic castrate-resistant prostate cancer AR; BEVI 2024-07-24
Dasatinib Y Y N Y 2006 Y DB01254 L01EA02 CHEMBL1421 Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML) TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3 2024-07-24
Daunorubicin N Y Y Y 1979 Y DB00694 L01DB02 CHEMBL178 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM 2024-07-24
Daunorubicin, Cytarabine Liposome Y Y N N 2017 Y DB00694 L01XY01; L01DB02 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia 2021-10-28
Decitabine Y Y N N 2006 Y DB01262 L01BC08 CHEMBL1201129 Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS) DNMT3A; CYP27B1; LIF; THBS1; IDH2; KRAS; CDKN2D; TP53; GSTP1; RB1; NR5A1; CDA; GMNN; TGM2; APC; MAGEA1; FLT3; CR2; HLA-E; CCND2; IDH1; CTAG1B; DNMT1; MUC2; IL2RA 2024-07-25
Decitabine , Cedazuridine Y Y N N 2020 N Not found in DrugBank L01BC58 Acute Myeloid Leukaemia 2023-08-01
Degarelix Y Y N N 2008 N DB06699 L02BX02 CHEMBL415606 Advanced Prostate Cancer GNRHR; GNRHR2 2024-07-24
Denileukin Diftitox N Y N N 1999 N DB00004 L01XX29 CHEMBL1201550 Cutaneous T-Cell Lymphoma (CTCL) IL2RG; IL2RB; EEF2; IL12RB1; IL12RB2; IL2RA 2024-07-24
Denosumab Y Y N N 2010 N DB06643 M05BX04 CHEMBL1237023 Giant cell tumor of the bone; Refractory Hypercalcemia of malignancy TNFSF11; TNFRSF11A; BRAF 2024-07-24
Dexamethasone Y Y N Y 1958 Y DB01234 S03BA01; S02BA06; S01CB01; S01BA01; R01AD03; H02AB02; D10AA03; D07XB05; D07AB19; C05AA09; A01AC02 CHEMBL384467 Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF) NR3C1; ANXA1; CDK4; CYP2C9; F2RL1; KDR; NRG1; NFE2L2; PTGDR; CHKA; CCL17; RARA; AR; TSC22D3; PZP; DOK5; HSPA8; CDK6; BDM; HTR7; SOAT1; CD86; CARTPT; CRISPLD2; GATA3; SI; CYP2C19; APOB; NR5A1; DPEP1; BMP7; FABP1; RPS19; CYP3A4; CDH17; CHRM3; PYGL; TDO2; CTNNB1; HYAL2; SAG; TYMS; ACTC1; MT1F; GSTP1; TJP1; THRSP; JAK3; S100A10; UBR1; NR1I2; NTRK1; AGTR1; PTH1R; F9; TEAD1; SLC2A4; VEGFA; KRT19; FOLR1; RET; SFTPA1; NPPC; CDK2; SDS; CYP1A2; TGFBR3; BIRC5; VCAM1; GGT1; LIF; IRS2; NR3C2; SERPINE1; IGFBP1; LINC00251; CYP2D6; CHAT; GLS; ALK; UGT1A1; BCL2L11; SMAD3; JUNB; TG; RELA 2024-07-25
Diethylstilbestrol N N Y N 1973 N DB00255 G03CC05; G03CB02; L02AA01 CHEMBL411 BDNF; ESRRB; SLC5A7; GMNN; PTGES3; CYP3A4; AMH; RORC; HRAS; CYP2D6; ESR2; BDKRB2; NPPC; LPO; BDKRB1; CYP1A2; AR; CP; NR1H4; CYP2C19; CYP2C9; NFE2L2; TP53; ERBB2; E2F1; BCYRN1P2; NR1I2; ESRRG; WNT7A; MYC; DNMT1; BCL2; ESR1 2024-07-24
Dinutuximab Y Y N N 2015 N DB09077 L01XC16 CHEMBL3137342 High Risk Neuroblastoma MYCN 2024-02-07
Docetaxel Y Y N Y 1996 Y DB01248 L01CD02 CHEMBL92 Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3 2024-07-24
Dostarlimab Y Y N N 2021 N DB15627 L01FF07 CHEMBL4298124 Adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen POLD1; PDCD1; POLE; MLH1; MSH2; PMS2; MSH6 2024-07-24
Doxorubicin N Y Y Y 1974 Y DB00997 L01DB01 CHEMBL53463 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A 2024-07-24
Doxorubicin Liposome Y Y N N 1998 Y Not found in DrugBank L01DB01 CHEMBL53463 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A 2024-07-24
Durvalumab Y Y N N 2017 N DB11714 L01FF03 CHEMBL3301587 Unresectable Stage III Non-small Cell Lung Cancer; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC) MSH2; IDH1; CD274; PMS2; MLH1; ATM; PDCD1; PBRM1; ALK; MSH6; EGFR 2024-07-24
Duvelisib Y Y N N 2018 N DB11952 L01EM04 CHEMBL3039502 Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R 2024-07-24
Edotreotide Y N N N 2019 N DB15494 V09IX09 CHEMBL408350 Neuroendocrine Tumors FASLG 2024-07-24
Eflornithine N Y N Y 2023 N DB06243 L01XX79 CHEMBL830 High Risk Neuroblastoma XIAP; JUN; EHMT2; ODC1; NR5A1; TGM2; KCNA1; MYCN; PRL; ATF2; SMOX 2024-07-24
Elacestrant Y Y N N 2023 N DB06374 L02BA04 CHEMBL4297509 Advanced Breast Cancer, Metastatic Breast Cancer ESR1; ERBB2 2024-07-24
Elotuzumab Y Y N N 2015 N DB06317 L01FX08 CHEMBL1743010 Refractory Multiple Myeloma GPR27; SLAMF7 2024-07-24
Elranatamab Y Y N N 2023 N DB15395 L01FX32 CHEMBL4297809 Relapsed or Refractory Multiple Myeloma TNFRSF17; CD3G; CD3D; CD3E 2024-07-24
Emapalumab N Y N N 2018 N DB14724 L04AA39 CHEMBL3989977 IFNG; PRF1; STXBP2; XIAP; SH2D1A; RAB27A; UNC13D; STX11 2024-07-24
Enasidenib N Y N N 2017 N DB13874 L01XX59 CHEMBL3989908 Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML) IDH2; FLT3; GRB2; IDH1 2024-07-24
Encorafenib Y Y N N 2018 N DB11718 L01EC03 CHEMBL3301612 Metastatic Melanoma; Unresectable Melanoma KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN 2024-07-24
Enfortumab Vedotin Y Y N N 2021 N DB13007 L01FX13 CHEMBL3301589 Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer NECTIN4 2024-02-07
Entrectinib Y Y N N 2019 N DB11986 L01EX14 CHEMBL1983268 Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN 2024-07-24
Enzalutamide Y Y N N 2012 N DB08899 L02BB04 CHEMBL1082407 Metastatic Castration Resistant Prostate Cancer BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR 2024-07-24
Epcoritamab Y Y N N 2023 N DB16672 L01FX27 CHEMBL4650393 Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL) CD3D; CD3G; CD3E; MS4A1 2024-07-24
Epirubicin N Y Y N 1999 Y DB00445 L01DB03 CHEMBL417 Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2 2024-07-24
Erdafitinib Y Y N N 2019 N DB12147 L01EN01 CHEMBL3545376 Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4 2024-07-24
Eribulin Y Y N N 2010 Y DB08871 L01XX41 CHEMBL1683590 Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma TERT; TUBB2A; TUBA3E; TUBA1C; ERBB2; TUBB3; TUBB4A; TUBB1; TUBA3C; CYP3A4; ESR1; GCF1; TUBB4B; TUB; ESR2; TUBA1A; TUBB2B; TUBB; PGR; TUBB8; TUBA4A; TUBB6; CD274; TUBA1B; CDK2 2024-07-25
Erlotinib Y Y N Y 2004 Y DB00530 L01EB02 CHEMBL553 Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1 2024-07-25
Estramustine N Y Y N 1981 N DB01196 L01XX11 CHEMBL1575 Metastatic Hormone Refractory Prostate Cancer TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1 2024-07-24
Etoposide N Y Y Y 1983 Y DB00773 L01CB01 CHEMBL44657 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1 2024-07-24
Everolimus Y Y N N 2009 Y DB01590 L04AA18; L01EG02 CHEMBL1908360 Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET 2024-07-25
Exemestane N Y Y N 1999 Y DB00990 L02BG06 CHEMBL1200374 Early Breast Cancer; Refractory, advanced Breast cancer CYP19A1; TCL1A; BGLAP; STK11; ESR1; ESR2; MAP4K4; CYP1B1; PGR; CPD; IGF1R; AKR1C3; NFE2L2; TUBB1; CCDC148; AR; ERBB2 2024-07-24
Fedratinib Y Y N N 2019 N DB12500 L01EJ02 CHEMBL1287853 JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1 2024-07-24
Fludarabine N Y Y Y 1991 Y DB01073 L01BB05 CHEMBL1568 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma MPO; NFE2L2; IKZF1; RRM1; POLA1; POLE3; PRIM2; BAX; POLD2; ADH1A; ATM; RRM2B; PIK3CG; POLA2; SLCO1B1; CYP2E1; POLD3; SLC29A1; SMAD3; POLD4; CXCL12; POLD1; POLE; SULT2B1; POLE2; DCK; SLC22A12; XIAP; RRM2; NIPSNAP2; PRIM1; GBA1LP; ADA; CD40 2024-07-24
Fluorouracil N Y Y Y 1962 Y DB00544 L01BC02 CHEMBL185 Breast Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Rectal Carcinoma; Superficial Basal Cell Carcinoma OR10AE3P; PERP; BDNF; GCKR; MECP2; RGS5; GNL3; NOS1; TYMS; FPGS; MUC2; DPYD; FOXO1; FGFR4; ABCC4; REV3L; HSPA5; IL11; CYP19A1; KRAS; CSPG4; PIK3R2; CYP3A4; CD274; ERCC1; LGR5; DLG5; OSGEP; TOP2A; NRAS; FAS; TP53AIP1; IGFBP3; MEGF11; XRCC3; CYP3A; KLC1; WNT5B; ATRX; PPP2R5D; ALCAM; EGFR; BRAF; PTEN; KCNQ1; IL6R; TMEM167A; SLC19A1; EXO1; ATM; CYP2E1; PIK3CA; ABCC1; TSHB; HBB; ITGAL; AURKA; DTYMK; CBR1; MSH6; E2F1; PMS2; ABCC2; ABCB1; CHN2; BIRC5; NT5C1A; RALBP1; CYP4X1; TP53; KLC3; ENOSF1; SELE; SCN1A; SMAD4; TYMP; TYMSOS; IGF2BP2; UPB1; RBX1; TWIST1; ABCC5; FGFR2; PTPRC; TPT1; COLEC10; CBR3; CXCL8; CYP2C8; PARD3B; CDKN1A; CYP2C19; PSMB3P1; MSH2; SLC22A16; DKK1; MLH1; MYB; CYP1B1; PDGFRB; MUTYH; IL2RA; CCNK; INSR; ALDH3A1; IRS1; GALNT14; APEX1; BAX; MAP2K1; GNAS; KEAP1; CYP2A6; HMMR; CCND1; CDC25C; NLGN1; MTHFR; ABCG1 2024-07-25
Fluoxymesterone N Y N N 1956 Y DB01185 G03BA01 CHEMBL1445 Inoperable, metastatic Breast cancer AR; NR3C1; BEVI; PRL 2024-07-24
Flutamide N Y Y N 1989 Y DB00499 L02BB01 CHEMBL806 C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A 2024-07-24
Fotemustine Y N N N DB04106 L01AD05 CHEMBL549386 Metastatic Melanoma MGMT; TXNRD1 2024-02-07
Fruquintinib Y Y N N 2023 N DB11679 L01EK04 CHEMBL4303214 Metastatic Colorectal Cancer KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS 2024-07-24
Fulvestrant Y Y N N 2002 Y DB00947 L02BA03 CHEMBL1358 Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer TP53; PGR; ESR2; ESR1; EML4; NOS1; EPHX2; ESRRA; FGF2; ERBB2; PIK3CA; PIK3CG; TFPI; BCYRN1P2; PTEN; RB1; CYP1A2; FGFR2; CCNE1; CDK6; XIAP; ALK; ALDH3B1; BDNF 2024-07-25
Futibatinib Y Y N N 2022 N DB15149 L01EN04 CHEMBL3701238 Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3 2024-07-24
Gefitinib Y Y N Y 2003 Y DB00317 L01EB01 CHEMBL939 Metastatic Non-Small Cell Lung Cancer PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1 2024-07-24
Gemcitabine N Y Y Y 1996 Y DB00441 L01BC05 CHEMBL888 Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma C6orf15; CYP2C8; NIPSNAP2; ATAT1; AR; WWOX; BRCA2; MDM2; GPX5; SLC29A1; RRM1; POLD1; RAF1; CIP2A; POLE3; TP53; POLD2; POLD4; FKBP5; CHEK1; FANCC; POLD3; CD274; FGFR3; XRCC1; PRIM2; NRAS; POLE2; SERPINC1; POLE; PSORS1C1; TNF; DDX53; NT5C; SERPINA5; RRM2B; BRCA1; PPP1R18; PRB2; CDA; DCP1B; CAMK4; UBASH3B; PRRC2A; MTHFD1; SH2D5; BRAF; PPP1R13L; TNC; OR4D6; DOCK8; PTEN; SLCO1B1; FHL2; IGF2; PPCDC; GBA1LP; ERCC1; RRM2; HCP5; MS4A2; HRAS; ESR2; PIK3CA; SMAD4; POLR1G; MTHFR; ETS2; CDKN2A; CDSN; NT5C1A; SLC29A2; BAZ2B; ACSS2; ALG10; NRG1; MUCL3; HLA-C; WEE1; CDC5L; BTRC; KLC3; XYLT2; MSH5; PRIM1; ALOX5AP; TGM2; CBL; KRAS; TENT4A; ERBB2; POLA2; POLA1 2024-07-24
Gemtuzumab Ozogamicin Y Y N N 2000 N DB00056 L01FX02 CHEMBL1201506 Acute Myeloid Leukemia (AML); Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML) CYP2E1; SULT2B1; CD33; CHEK1; SLC22A12; SLCO1B1; ADH1A; PML; GAPDHP60; ABCB1 2024-07-24
Gilteritinib Y Y N N 2018 N DB12141 L01EX13 CHEMBL3301622 Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B 2024-07-24
Glasdegib Y Y N N 2018 N DB11978 L01XJ03 CHEMBL2043437 Acute Myeloid Leukemia (AML) SMO; ALOX12; MTOR; FLT3 2024-07-24
Glofitamab Y Y N N 2023 N DB16371 L01FX28 CHEMBL4298092 Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified CD3E; MS4A1; CD3G; CD3D 2024-07-24
Goserelin N Y Y N 1989 N DB00014 L02AE03 CHEMBL1201247 Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR 2024-07-24
Histamine dihydrochloride Y Y N N 1939 N DB05381 L03AX14 CHEMBL90 Acute Myeloid Leukaemia AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA 2024-07-24
Histrelin N Y N N 1991 N DB06788 L02AE05 CHEMBL1201255 Advanced Prostate Cancer GNRHR; GNRHR2 2024-02-07
Hydroxyurea N Y N N 1967 Y DB01005 L01XX05 CHEMBL467 Essential Thrombocythemia (ET); Head and Neck Carcinoma; Melanomas; Ovarian Cancer Metastatic; Polycythemia Vera (PV); Chronic, refractory Myeloid Leukemia; Inoperable Ovarian cancer BLM; PTH; DNMT1; EIF4E; JAK2; TET2; ABL1; MAP3K5; DUSP1; GBA1LP; RRM1; CP; HRAS; ASS1; SIN3A; CYP3A4; NIPSNAP2; KLF4; RRM2B; RRM2; DNTT 2024-07-25
Ibritumomab Tiuxetan Y Y N N 2002 N DB00078 V10XX02 CHEMBL1201606 Follicular Non-Hodgkin's Lymphoma; Follicular Non-Hodgkin's Lymphoma Refractory GATM; MS4A1 2024-07-24
Ibrutinib Y Y N N 2013 N DB09053 L01EL01 CHEMBL1873475 Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM) CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2 2024-07-24
Idarubicin N Y Y N 1990 Y DB01177 L01DB06 CHEMBL1117 Acute Myeloid Leukemia (AML) CBX1; CBR3; CYP2E1; CSF2; POLH; RAPGEF3; FLT3; POLB; SLCO1B1; ETV6; POLI; NQO1; TOP2A; SULT2B1; THRB; ATAD5; FEN1; KCNH2; MPHOSPH8; APEX1; EHMT2; ABCB1; ATXN2; WRN; DRD1; IDH1; MTOR; ERG; PPARD; NT5C3A; HTT; AR; NCF4; USP1; BLM; RECQL; quinone dehydrogenase 2; SLC22A12; DCK; MAPT; BRD10; ADH1A; POLK; RAC2; PLK1; DNMT3A; CYBA; RAPGEF4 2024-07-24
Idecabtagene Vicleucel Y Y N N 2021 N DB16665 L01XL07 CHEMBL4298199 Refractory Multiple Myeloma, Relapsed Multiple Myeloma TNFRSF17 2024-02-07
Idelalisib Y Y N N 2014 N DB09054 L01EM01 CHEMBL2216870 Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R 2024-07-24
Ifosfamide N Y Y Y 1988 Y DB01181 L01AA06 CHEMBL1024 Cancer, Bladder; Cervical Cancers; Ewing's Sarcoma; Head and Neck Carcinoma; Lymphoma, Hodgkins; Malignant Neoplasm of Pancreas; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Testicular Germ Cell Cancer; Advanced thymic carcinoma TERC; KLC3; IL6; CYP2A6; DNMT1; GSTP1; TP53; ALDH1A1; CYP2B6; ERCC2; ALK; HSPA4; NR1I2; MGMT 2024-07-24
Imatinib Y Y N Y 2001 Y DB00619 L01EA01 CHEMBL941 Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT 2024-07-25
Imiquimod Y Y N N 1997 Y DB00724 D06BB10 CHEMBL1282 Superficial Basal Cell Carcinoma TLR7; IFNA1; SARDH; GMNN 2024-07-25
Inavolisib N Y N N 2024 DB15275 CHEMBL4650215 Locally advanced or metastatic breast cancer PIK3CG; FGFR2; PIK3CA 2024-11-28
Infigratinib N Y N N 2021 N DB11886 L01EN03 CHEMBL1852688 Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3 2024-07-24
Inotuzumab Ozogamicin Y Y N N 2017 N DB05889 L01FB01 CHEMBL2108611 Refractory B-cell precursor acute lymphoblastic leukemia; Relapsed B cell precursor Acute lymphoblastic leukemia ABL1; GNG4; CD22; BCR 2024-07-24
Interferon Alfa-2b Y Y N N 1986 N DB00105 L03AB05 CHEMBL1201558 Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX 2024-07-24
Iobenguane I-131 N Y N N 1994 N DB06704 V09IX01; V09IX02; V10XA02 CHEMBL1615779 Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas SLC6A2; TH 2024-07-24
Ipilimumab Y Y N N 2011 N DB06186 L01FX04 CHEMBL1789844 Advanced Renal Cell Carcinoma; Cutaneous Melanoma; Hepatocellular Carcinoma; Metastatic Melanoma; Unresectable Melanoma; Metastatic MSI-H/dMMR colorectal cancer NRAS; MLH1; TP53; CD274; GLRB; BRAF; ALK; ATM; PTEN; POLE; POLD1; HLA-A; MSH6; MSH2; MDM2; B2M; PMS2; EGFR; CTLA4; PBRM1 2024-07-24
Irinotecan N Y Y Y 1996 Y DB00762 L01CE02 CHEMBL481 Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274 2024-07-24
Irinotecan Liposome Y Y N N 1996 Y DB00762 L01XX19 CHEMBL481 Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274 2024-07-24
Isatuximab Y Y N N 2020 N DB14811 L01FC02 CHEMBL3545131 Multiple Myeloma (MM) GMPR 2024-07-24
Ivosidenib Y Y N N 2018 N DB14568 L01XX62 CHEMBL3989958 Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation IDH2; GPX1P2; IDH1 2024-07-24
Ixabepilone N Y N N 2007 N DB04845 L01DC04 CHEMBL1201752 Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer ESR1; TUBB; ERBB2; TUBA1C; TUBB2B; TUBA3C; TUBB1; TUBA4A; PGR; TUBB8; TUBA1B; TUBB3; TUBA1A; TUBB2A; ESR2; CYP3A4; TUBA3E; TUBB4B; TUBB4A; TUBB6; TUB; GCF1 2024-07-24
Ixazomib Y Y N N 2015 N DB09570 L01XG03 CHEMBL2141296 Multiple Myeloma (MM) PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9 2024-07-24
Lanreotide N Y Y N 2007 Y DB06791 H01CB03 CHEMBL1201185 Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG 2024-07-25
Lapatinib Y Y N N 2007 Y DB01259 L01EH01 CHEMBL554 Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1 2024-07-24
Larotrectinib Y Y N N 2018 N DB14723 L01EX12 CHEMBL3889654 NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive NTRK1; NTRK3; NTRK2; DRD5P1 2024-07-24
Lazertinib N Y N N 2024 DB16216 L01EB09 CHEMBL4558324 First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) EPHB3; DXO; EGFR; DRD2; FDX1 2024-11-28
Lenalidomide Y Y N Y 2005 Y DB00480 L04AX04 CHEMBL848 Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma TNFSF11; RBX1; VEGFC; VEGFB; CUL4A; DDB1; KDR; TP53; TNF; CTNNB1; VEGFA; CRBN; FGF2 2024-07-25
Lenvatinib Y Y N N 2015 N DB09078 L01EX08 CHEMBL1289601 Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3 2024-07-24
Letrozole N Y Y N 1997 Y DB01006 L02BG04 CHEMBL1444 Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613 2024-07-25
Leuprolide N Y N N 1985 Y DB00007 L02AE51; L02AE02 CHEMBL1201199 Advanced Prostate Cancer CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4 2024-07-24
Lifileucel N Y N N 2024 N DB17107 L01XL11 CHEMBL4298200 Unresectable or metastatic melanoma 2024-04-24
Lisocabtagene Maraleucel Y Y N N 2021 N DB16582 L01XL08 CHEMBL4297236 Grade 3b Follicular Lymphoma; High-grade B-cell Lymphoma (HGBCL); Primary mediastinal large B-cell lymphomas; Refractory Diffuse Large B Cell Lymphoma; Refractory Large B-cell Lymphoma; Relapsed Large B-cell Lymphoma; Relapsed, Diffuse Large B-cell Lymphoma, Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) CD19 2024-07-31
Lomustine N Y Y N 1976 N DB01206 L01AD02 CHEMBL514 Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain IDH1; MGMT; ADK; EGFR 2024-07-24
Loncastuximab Tesirine Y Y N N 2021 N DB16222 L01FX22 CHEMBL4297778 Refractory Large B-cell Lymphoma, Relapsed Large B-cell Lymphoma CD19 2024-02-07
Lorlatinib Y Y N N 2018 N DB12130 L01ED05 CHEMBL3286830 Progressive, metastatic Anaplastic lymphoma kinase-positive Metastatic Non-Small Cell Lung Cancer EML4; ROS1; FGFR1; ENO1; ALK; PIK3CA; NRAS; HRAS; RB1; TP53; BRAF; DTX1; HBEGF 2024-07-24
Lu 177-Dotatate Y Y N N 2018 N DB13985 V10XX04 CHEMBL3989924 Gastroenteropancreatic Neuroendocrine Tumors SSTR1; SSTR5; SSTR3; SSTR2; SSTR4 2024-07-24
Lurbinectedin N Y N N 2020 N DB12674 L01XX69 CHEMBL4297516 Metastatic Small Cell Lung Cancer 2020-09-17
Lutetium Lu 177 Vipivotide Tetraxetan Y Y N N 2022 N DB16778 V10XX05 CHEMBL4594406 Metastatic Castration Resistant Prostate Cancer (CRPC) FOLH1 2024-02-07
Margetuximab N Y N N 2020 N DB14967 L01FD06 CHEMBL2364649 HER2-positive Metastatic Breast Cancer EN1 2024-07-24
Mechlorethamine Y Y N N 1949 N DB00888 L01AA05 CHEMBL427 Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion MMP2; GSR; GSTP1; CXCR2; NOS1; BAX; ERBB2; MT-CO1; XRCC1; TSHB; CSF2 2024-07-24
Medroxyprogesterone N Y Y N 1959 Y DB00603 G03DA02; G03AC06; L02AB02 CHEMBL717 Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma BAX; PGR; VDR; MMP1; CYP1B1; ESR1; CYP3A5 2024-07-24
Megestrol Acetate N Y Y N 1971 Y DB00351 G03DB02; G03AC05; L02AB01 CHEMBL1201139 Advanced Breast Cancer; Advanced Endometrial Cancer ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2 2024-07-25
Melphalan N Y Y Y 1964 Y DB01042 L01AA03 CHEMBL852 Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53 2024-07-25
Melphalan Flufenamide Y Y N N 2021 N DB16627 L01AA10 CHEMBL4303060 Relapsed Or Refractory Multiple Myeloma CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53 2024-07-24
Mercaptopurine Y Y N Y 1953 Y DB01033 L01BB02 CHEMBL1425 Acute Lymphoblastic Leukaemias (ALL); Acute Promyelocytic Leukemia (APL); Lymphoma, Lymphoblastic IDH1; KDM4A; BAZ2B 2024-07-24
Methotrexate Y Y N Y 1953 Y DB00563 L04AX03; L01BA01 CHEMBL34259 Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8 2024-07-25
Midostaurin Y Y N N 2017 N DB06595 L01EX10 CHEMBL608533 Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1 2024-07-24
Mifamurtide Y N N N 2009 N DB13615 L03AX15 CHEMBL2107354 High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma NOD2 2024-02-07
Mirvetuximab Soravtansine Y Y N N 2022 N DB12489 L01FX26 CHEMBL3545132 Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer HOXB2 2024-07-24
Mitomycin N Y Y N 1981 Y DB00305 L01DC03 CHEMBL105 Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC) IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1 2024-07-25
Mitoxantrone N Y Y N 1987 Y DB01204 L01DB07 CHEMBL58 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1 2024-07-24
Mobocertinib N Y N N 2021 N DB16390 L01EB10 CHEMBL4650319 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer EGFR 2024-02-07
Mogamulizumab Y Y N N 2018 N DB12498 L01FX09 CHEMBL1743041 Refractory Mycosis Fungoides/Sezary Syndrome; Relapsed Mycosis Fungoides/Sezary Syndrome CCR4 2024-07-24
Mosunetuzumab Y N N N 2022 N DB15434 L01FX25 CHEMBL4297788 Relapsed follicular lymphoma, Refractory follicular lymphoma MS4A1; CD3D; CD3G; CD3E 2024-07-24
Moxetumomab Pasudotox Y Y N N 2018 N DB12688 L01FB02 CHEMBL1743043 Relapsed/Refractory Hairy Cell Leukemia CD22; GNG4; EEF2 2024-07-24
Nab-Paclitaxel Y Y N N 2005 Y Not found in DrugBank L01CD01 CHEMBL428647 Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A 2024-07-24
Nab-Sirolimus N Y N N 2021 Y DB00877 L04AH01 CHEMBL413 Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) TP53; TSC1; PIK3CA; IL10; CTLA4; MTOR; ITGAL; CDKN2A; CRLF2; FBXW7; RHEB; FKBP1A; ABCG2; IL17A; NR1I2; NFE2L2; NF1; PTEN; IL15; ABCB1; PLAU; DCN; AR; PGR; TGM2; STK11; APC; EGFR; MMP1; OPRK1; HRAS; FKBP4; IL7; ALK; FGF2; RB1; EML4; WT1; FLCN; NOS1; RPTOR; IGFBP1; BAX; EIF4E; DDC; DDIT3; NRAS; ADAMTSL4-AS1; TCF7L2; ERBB2; RPS6KB1; PIM1; FGFR1; PRKAA1; MAPK10; RBL2; GAPDHP67 2024-07-25
Nadofaragene Firadenovec N Y N N 2022 N DB17381 L01XL10 CHEMBL3990041 High risk BCG-unresponsive non-muscle invasive bladder cancer IFNA2 2024-02-07
Naxitamab N Y N N 2020 N DB15965 L01FX21 CHEMBL4297984 High risk, refractory Neuroblastomas of the bone or bone marrow; High risk, relapsed Neuroblastomas of the bone or bone marrow 2022-10-23
Necitumumab Y Y N N 2015 N DB09559 L01FE03 CHEMBL1743047 Metastatic Non-Small Cell Lung Cancer EGFR; DXO 2024-07-24
Nelarabine Y Y N N 2005 Y DB01280 L01BB07 CHEMBL1201112 Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia POLA1; NT5C2 2024-02-07
Neratinib Y Y N N 2017 N DB11828 L01EH02 CHEMBL180022 Breast Cancer KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2 2024-07-24
Nilotinib Y Y N Y 2007 N DB04868 L01EA03 CHEMBL255863 Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1 2024-07-24
Nilutamide N Y N N 1996 Y DB00665 L02BB02 CHEMBL1274 Metastatic Hormone Refractory Prostate Cancer KLK3; AR; CYP2C9; CYP2D6; NFE2L2; CYP2C19; CYP1A2; PRL; BEVI; CYP3A4 2024-07-24
Nintedanib Y Y N N 2014 Y DB09079 L01EX09 CHEMBL502835 Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET 2024-07-24
Niraparib Y Y N N 2017 N DB11793 L01XK02 CHEMBL1094636 Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2 2024-07-24
Nirogacestat Hydrobromide N Y N N 2023 N DB12005 L01XX81 CHEMBL4298153 Progressive Desmoid Tumors PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1 2024-11-28
Nivolumab Y Y N Y 2015 N DB09035 L01FF01 CHEMBL2108738 Advanced Renal Cell Cancer; Classical Hodgkin's Lymphoma; Hepatocellular Carcinoma; Low Risk Advanced Renal Cell Cancer; Melanomas; Metastatic Colorectal Cancer (MCRC); Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Metastatic Small Cell Lung Cancer; Metastatic Squamous Cell Carcinoma of the Head and Neck; Metastatic Urothelial Carcinoma (UC); Recurrent Head and Neck Squamous Cell Carcinoma; Unresectable Melanoma; Intermediate risk Advanced Renal Cell Cancer; Locally advanced Urothelial Carcinoma FGFR3; CD274; ALK; BRAF; POLE; ATM; PTEN; GM2A; PIK3CA; MLH1; MDM2; PBRM1; EGFR; LAG3; B2M; POLD1; MDM4; ARID1A; MSH2; TP53; IDH1; HLA-DRA; STK11; MSH6; PMS2; NRAS; PDCD1; CDK12; KRAS; ERBB2 2024-07-24
Obinutuzumab Y Y N N 2013 N DB08935 L01FA03 CHEMBL1743048 Refractory Follicular Lymphoma; Previously untreated Chronic lymphocytic leukemia GATM; TP53; MS4A1 2024-07-24
Odronextamab Y N N N 2024 DB16684 CHEMBL4298084 Relapsed/refractory B-Cell non-Hodgkin lymphoma GATM 2024-07-25
Ofatumumab Y Y N N 2009 N DB06650 L04AA52; L01FA02 CHEMBL1201836 Chronic Lymphocytic Leukaemia (CLL); Chronic Lymphocytic Leukemia (CLL) - Refractory; Progressive Chronic Lymphocytic Leukaemia (CLL); Recurrent Chronic Lymphocytic Leukaemia (CLL) MS4A1; GATM 2024-07-24
Olaparib Y Y N N 2014 N DB09074 L01XK01 CHEMBL521686 Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3 2024-07-24
Olaratumab Y Y N N 2016 N DB06043 L01FX10 CHEMBL1743049 Soft Tissue Sarcoma (STS) PDGFRA; DPP4 2024-07-24
Olutasidenib N Y N N 2022 N DB16267 CHEMBL4297610 Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML) IDH1; GPX1P2 2024-07-24
Omacetaxine Mepesuccinate N Y N N 2009 N DB04865 L01XX40 CHEMBL46286 Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia BIRC5; FLT3; TERT; BCR; ABL1 2024-07-24
Osimertinib Y Y N N 2015 N DB09330 L01EB04 CHEMBL3353410 Metastatic Non-Small Cell Lung Cancer EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS 2024-07-24
Oxaliplatin N Y Y Y 2002 Y DB00526 L01XA03 CHEMBL414804 Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer DPYD; GSTP1; PARD3B; GNA13; BCL2; BRAF; BRCA1; ABCC1; CD274; DKK1; FOXC2; FGFR2; MLH1; CXCL10; ATP7A; KRAS; ABL1; ABCC5; KCNQ1; IGF2BP2; TP53; PIN1; MTHFR; GCKR; PMS2; ZEB1; SELE; MSH2; BAX; XRCC3; MSH6; PTEN; ATM; PTGS2; CSMD1; ATP7B; KLC3; MGAT4A; PIK3CA; MT1A; ABCC2 2024-07-25
Paclitaxel Y Y N Y 1992 Y DB01229 L01CD01 CHEMBL428647 Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A 2024-07-24
Padeliporfin Y N N N 2017 N DB15575 L01XD07 CHEMBL4298112 Low-Risk Prostate Cancer of the one lobe only 2020-09-17
Palbociclib Y Y N N 2015 N DB09073 L01EF01 CHEMBL189963 Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3 2024-07-24
Panitumumab Y Y N N 2006 N DB01269 L01FE02 CHEMBL1201827 Metastatic Colorectal Cancer (MCRC) NRAS; NRG2; EGFR; TGFA; CDKN2A; KRAS; AREG; NRG3; MET; TP53; NRG1; PTEN; DXO; PIK3CA; BTC; HBEGF; BRAF; EREG; HRAS; MAP2K1 2024-07-24
Panobinostat Y Y N N 2015 N DB06603 L01XH03 CHEMBL483254 Refractory Multiple Myeloma HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A 2024-07-24
Pazopanib Y Y N N 2009 Y DB06589 L01EX03 CHEMBL477772 Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2 2024-07-25
Pegaspargase Y Y N Y 1994 N DB00059 L01XX24 CHEMBL2108546 Acute Lymphoblastic Leukaemias (ALL) HLA-DRB1; APOC3; HLA-DQA1; TPMT; CPT1A; PNPLA3; UGT1A1; ARHGAP28; BMP7; IGHMBP2; LINC00251; DOK5; GATA3; HLA-DQB1; APOA5 2024-07-24
Peginterferon Alfa-2b Y Y N N 2001 N DB00022 L03AB10 CHEMBL1201561 Melanomas DHODH; IFIT1; IL6; EGFR; JAK2; MICB; HLA-DPA1; CARD16; CTLA4; IFNAR2; CXCL10; OAS1; IFNL3; IFNA2; IL21R; CASP1; IFNAR1; IL18; KLRK1; SLC29A1; VDR; KIR2DS2; SLC6A4; HLA-A; OASL; DNAAF9; SLC28A2; SOCS3; HLA-C; CYP2R1; TUT7; HLA-B 2024-07-24
Pembrolizumab Y Y N Y 2014 N DB09037 L01FF02 CHEMBL3137343 Advanced Renal Cell Carcinoma; Cervical Cancers; Colorectal Cancers; Metastatic Melanoma; Metastatic Solid Tumors; Unresectable Melanoma; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Locally advanced gastroesphageal juntion adenocarcinoma; Metastatic gastroesphageal juntion adenocarcinoma; Metastatic nonsquamous non-small cell lung cancer; Recurrent, metastatic Head and Neck Squamous Cell Carcinoma; Refractory, metastatic Non small cell lung cancer; Refractory, relapsed Hodgkin Lymphoma; Refractory, relapsed Mediastinal Large B-cell Lymphoma; Unresectable Solid Tumors ARID1A; EGFR; JAK1; ROS1; POLE; PBRM1; KEAP1; MSH2; PDCD1; MDM4; GM2A; BRAF; FBXW7; JAK2; ERBB2; PDCD1LG2; CD274; MLH1; TP53; PTEN; KIT; KRAS; STK11; MSH6; ALK; IDH1; B2M; POLD1; CDK12; PMS2; NRAS; MDM2; MET; PIK3CA; HLA-DRA 2024-07-24
Pemetrexed Y Y N N 2004 Y DB00642 L01BA04 CHEMBL225072 Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1 2024-07-25
Pemigatinib Y Y N N 2020 N DB15102 L01EN02 CHEMBL4297522 Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1 2024-07-24
Pentostatin N N Y N 1991 Y DB00552 L01XX08 CHEMBL1580 B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome CCR1; PRKAA1; ADA 2024-07-24
Pertuzumab Y Y N N 2012 N DB06366 L01FD02 CHEMBL2007641 Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer 2024-07-24
Pertuzumab, Trastuzumab, Hyaluronidase Y Y N N 2020 Not found in DrugBank L01XY02 2021-10-28
Pipobroman N N Y N 1966 DB00236 L01AX02 CHEMBL1585 NFE2L2; KDM4E; ALDH1A1 2024-07-24
Pirarubicin N N N Japan N DB11616 L01DB08 CHEMBL2354444 ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1 2024-07-24
Pirtobrutinib Y Y N N 2023 N DB17472 L01EL05 CHEMBL4650485 Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma BTK; TP53; EFNB2; IGH 2024-07-24
Pixantrone Y N N N 2012 N DB06193 L01DB11 CHEMBL167731 Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma TOP2A 2024-02-07
Polatuzumab Vedotin Y Y N N 2019 N DB12240 L01FX14 CHEMBL3301582 Diffuse Large B-Cell Lymphoma (DLBCL) CD79B; TUBB4A; TUBB8; TUBA1B; TUBB4B; BCL6; BCL2; TUBB2A; TUBB; TUBA3E; TUBA1C; TUBB3; TUBB6; TUBB2B; TUBB1; TUBA1A; TUBA3C; MYC; TUBA4A 2024-07-24
Polyestradiol Phosphate N N Y N 1957 DB09369 L02AA02 CHEMBL1201477 ESR1; NOS1; AFP 2024-07-24
Pomalidomide Y Y N N 2013 Y DB08910 L04AX06 CHEMBL43452 Refractory Multiple Myeloma CRBN; RBX1; CUL4A; DDB1 2024-07-24
Ponatinib Y Y N N 2012 N DB08901 L01EA05 CHEMBL1171837 Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET 2024-07-24
Porfimer Y Y N N 1995 N DB00707 L01XD01 CHEMBL1201481 Esophageal Cancers; Completely obstructive Non-small cell lung cancer; Microinvasive endobrachial Non-small cell lung cancer; Partially obstructive Non-small cell lung cancer 2020-09-17
Pralatrexate Y Y N N 2009 Y DB06813 L01BA05 CHEMBL1201746 Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified DHFR; PDF; RFC1 2024-07-24
Pralsetinib Y Y N N 2020 N DB15822 L01EX23 CHEMBL4297597 Metastatic RET-fusion Non Small Cell Lung Cancer EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET 2024-07-24
Prednisolone Y Y N Y 1955 Y DB00860 S03BA02; S02BA03; S01CB02; S01BA04; R01AD02; H02AB06; D07XA02; D07AA03; C05AA04; A07EA01 CHEMBL131 Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF) LCAT; PNPLA3; CYP3A4; ALPP; NR3C1; DSE; NFE2L2; FCGR3A; FCGR3B; CYBA; MTHFR; TSPYL1; GATA3; AR; RAC2; NR3C2; CYP3A5; BDM; TAT; G6PD; HMGB1; BGLAP; RPS19; CD34; PLG; TG; ANXA1; BAX 2024-07-25
Prednisone N Y Y N 1955 Y DB00635 H02AB07; A07EA03 CHEMBL635 Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF) BMP7; TYMS; GSTM1; GSTP1; MIR4268; MC2R; NOS3; DOK5; ITGB2; TG; CXCL12; CYP3A5; CALCA; CYP3A4; VWF; MIR3117; CYP2C9; SLC19A1; TYMSOS; GSTA1; TPMT; IFNG; CYP1A2; GATA3; PTPRC; APOE; LINC00251; NCF4; AR; MYC; MBP; HSD17B10; NR3C1; NFATC1; CTLA4; CYBA; EDNRA; ABCB1; ATF5; BDM; ANXA1; CYP2D6; CYP2C19 2024-07-25
Procarbazine N Y Y Y 1969 N DB01168 L01XB01 CHEMBL1321 Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15 2024-07-24
Quizartinib Y Y N N 2023 N DB12874 L01EX11 CHEMBL576982 Newly Diagnosed Acute Myeloid Leukemia (AML) DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2 2024-07-24
Racotumomab N N N Cuba, Argentina N DB13045 CHEMBL1743059 2020-09-17
Radium 223 Dichloride Y Y N N 2013 N DB08913 V10XX03 CHEMBL2107816 Castration resistant, metastatic Prostate cancer 2020-09-17
Raltitrexed N N Y Canada N 1996 N DB00293 L01BA03 CHEMBL225071 Advanced Colorectal Cancer; Pleural Mesotheliomas CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR 2024-07-24
Ramucirumab Y Y N N 2014 N DB05578 L01FG02 CHEMBL1743062 Advanced Gastric Cancer; Advanced gastro-esophageal junction adenocarcinoma; Refractory, metastatic Colorectal cancer; Refractory, metastatic Non small cell lung cancer KDR; PDGFRA; EGFR; KRAS; DRD2; ALK 2024-07-24
Ranimustine N N N Japan N DB13832 L01AD07 CHEMBL2105348 2020-09-22
Realgar-Indigo Naturalis Formulation N N N China Y 2009 Not found in DrugBank L01XX27 Acute promyelocytic leukaemia 2021-03-10
Regorafenib Y Y N N 2012 N DB08896 L01EX05 CHEMBL1946170 Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4 2024-07-24
Relatlimab , Nivolumab Y Y N N 2022 DB14851 L01XY03 CHEMBL3990044; CHEMBL2108738 Metastatic Melanoma, Unresectable Melanoma 2024-07-25
Relugolix Y Y N N 2020 N DB11853 L02BX04 CHEMBL1800159 Advanced Prostate Cancer GNRHR; LHCGR 2024-02-07
Repotrectinib N Y N N 2023 N DB16826 L01EX28 CHEMBL4298138 locally active or metastatic non-small cell lung cancer EML4; NTRK3; ALK; ROS1; DTX1; NTRK1; DRG2; EPHB2; DRD5P2; HBEGF; DRD5P1 2024-07-24
Retifanlimab Y Y N N 2023 N DB15766 L01FF10 CHEMBL4298037 Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma GM2A 2024-07-24
Ribociclib Y Y N N 2017 N DB11730 L01EF02 CHEMBL3545110 Advanced Breast Cancer; Metastatic Breast Cancer CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A 2024-07-24
Ripretinib Y Y N N 2020 N DB14840 L01EX19 CHEMBL4216467 Advanced Gastrointestinal Stromal Tumor (GIST) CYP3A4; KIT; PDGFRB; PDGFRA; DPT 2024-07-24
Rituximab Y Y N Y 1997 N DB00073 L01FA01 CHEMBL1201576 Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (NHL) ABCB1; ERBB2; TET2; MS4A1; KRAS; FCGR3A; CYBA; ARID1A; IFNG; IL2; NCF4; GATM; CD274; RPS19; PIK3CA; TGFB1; CD38; EGFR; EN1; GMPR; JAK2; PIK3CG; PGR; EPCAM; NRG1; CBR3; PPCDC; IL6; MET; ANXA1; TP53; FCGR2A; GSTA1; HSPB2; CXCL12; AKT2; XIAP; RNF8; HGF; ESR1; ERBB3; CXCL13; PTEN; BIRC5; ESR2 2024-07-24
Rituximab, Hyaluronidase N Y N N 1997 N DB00073 L01XC02 CHEMBL1201576 Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (NHL) ABCB1; ERBB2; TET2; MS4A1; KRAS; FCGR3A; CYBA; ARID1A; IFNG; IL2; NCF4; GATM; CD274; RPS19; PIK3CA; TGFB1; CD38; EGFR; EN1; GMPR; JAK2; PIK3CG; PGR; EPCAM; NRG1; CBR3; PPCDC; IL6; MET; ANXA1; TP53; FCGR2A; GSTA1; HSPB2; CXCL12; AKT2; XIAP; RNF8; HGF; ESR1; ERBB3; CXCL13; PTEN; BIRC5; ESR2 2024-07-24
Romidepsin Y Y N N 2009 Y DB06176 L01XH02 CHEMBL343448 Refractory peripheral cutaneous T-cell lymphoma BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7 2024-07-24
Rucaparib Y Y N N 2016 N DB12332 L01XK03 CHEMBL1173055 Advanced Ovarian Cancer PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2 2024-07-24
Ruxolitinib Y Y N N 2011 N DB08877 L01EJ01 CHEMBL1789941 Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3 2024-07-24
Sacituzumab Govitecan Y Y N N 2020 N DB12893 L01FX17 CHEMBL3545262 Metastatic Triple-negative Breast Cancer ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2 2024-07-24
Selinexor Y Y N N 2019 N DB11942 L01XX66 CHEMBL3545185 Refractory Multiple Myeloma FLT3; TET2; TP53; XPO1; H2AX 2024-07-24
Selpercatinib Y Y N N 2020 N DB15685 L01EX22 CHEMBL4559134 Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer RET; KIF5B; PTK2B; CCDC6 2024-07-24
Sipuleucel-T N Y N N 2010 N DB06688 L03AX17 CHEMBL1237024 Asymptomatic, metastatic hormone-refractory Prostate cancer; Minimally symptomatic, metastatic hormone-refractory Prostate cancer ACP3 2024-02-07
Sonidegib Y Y N N 2015 N DB09143 L01XJ02 CHEMBL2105737 Refractory, locally advanced Basal cell carcinoma PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN 2024-07-24
Sorafenib Y Y N N 2005 Y DB00398 L01EX02 CHEMBL1336 Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7 2024-07-24
Sotorasib Y Y N N 2021 N DB15569 L01XX73 CHEMBL4535757 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer KRAS; HRAS; NRAS 2024-07-24
Streptozocin N Y N N 2005 N DB00428 L01AD04 CHEMBL1651906 Stage 4 islet cell carcinoma SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3 2024-07-24
Sugemalimab Y N N N 2024 DB16641 L01FF11 CHEMBL4594535 Metastatic non-small cell lung cancer (NSCLC) CD274 2024-11-28
Sunitinib Y Y N N 2006 Y DB01268 L01EX01 CHEMBL535 Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1 2024-07-25
Tafasitamab Y Y N N 2020 N DB15044 L01FX12 CHEMBL4298047 Refractory Diffuse large B-cell lymphoma NOS; Relapsed Diffuse large B-cell lymphoma NOS GMFB; TNFRSF8; CD19 2024-07-24
Tagraxofusp Y Y N N 2018 N DB14731 L01XX67 CHEMBL4297573 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) CSF2RB; EEF2; IL3RA 2024-07-24
Talazoparib Y Y N N 2018 N DB11760 L01XK04 CHEMBL3137320 Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer MYCN; CDK12; MLH1; STK11; BRCA2; FLT3; SLFN11; PARP2; ATRX; GNAI2; ATR; BRAF; GNAI2P1; PSMD4; PARP1; NRAS; ARID1A; IDH1; EGFR; DNMT3A; ERBB2; IDH2; ATM; BRCA1; TET2; PALB2; PTEN 2024-07-24
Talimogene Laherparepvec Y Y N N 2015 N DB13896 L01XX51 CHEMBL2108727 Unresectable Skin Lesion CSF2; CSF2RA 2024-07-24
Talquetamab Y Y N N 2023 N DB16678 L01FX29 CHEMBL4594503 Relapsed and Refractory Multiple Myeloma CD3G; GPRC5D; CD3E; CD3D 2024-07-24
Tamoxifen N Y Y Y 1977 Y DB00675 L02BA01 CHEMBL83 Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1 2024-07-24
Tarlatamab N Y N N 2024 N DB17256 L01FX33 CHEMBL5095292 Extensive-stage small cell lung cancer GLRA2 2024-07-24
Tazemetostat N Y N N 2020 N DB12887 L01XX72 CHEMBL3414621 Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A 2024-07-24
Tebentafusp Y Y N N 2022 N DB15283 L01XX75 CHEMBL4297990 Metastatic Uveal Melanoma (UM), Unresectable Uveal Melanoma PMEL; TRBV20OR9-2; HLA-A; CD3G 2024-07-24
Teclistamab Y Y N N 2022 N DB16655 L01FX24 CHEMBL4594505 Multiple Myeloma CD3D; CD3E; CD3G; TNFRSF17 2024-07-24
Tegafur, Gimeracil, Oteracil Y N N N 2011 DB09256 L01BC03; L01BC53 CHEMBL20883 Advanced Gastric Cancer TYMP 2024-07-24
Tegafur, Uracil N N N Japan N DB09256 L01BC03; L01BC53 CHEMBL20883 Advanced Gastric Cancer TYMP 2024-07-24
Temoporfin Y N N N 2001 N DB11630 L01XD05 CHEMBL500576 Advanced Head and Neck Squamous Cell Carcinoma 2020-09-17
Temozolomide Y Y N N 1999 Y DB00853 L01AX03 CHEMBL810 Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome PIK3CA; MGMT; HDAC4; PTEN; ATRX; TP53; MYC; IDH1; H2AX; BRCA2; GSTP1; CDKN2A; ATR; PRL; MSH6; CSF2; ALK; ARID1A; ATM; SLFN11 2024-07-24
Temsirolimus Y Y N N 2007 Y DB06287 L01EG01 CHEMBL1201182 Advanced Renal Cell Carcinoma NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD 2024-07-24
Tepotinib Y Y N N 2021 N DB15133 L01EX21 CHEMBL3402762 Metastatic Non-Small Cell Lung Cancer MET; EGFR; DRD4; ALK 2024-07-24
Thalidomide Y Y N Y 1998 N DB01041 L04AX02 CHEMBL468 Multiple Myeloma (MM); Waldenstrom's Macroglobulinemia (WM); Treatment naive multiple myeloma FCGR3B; FGFR2; DDB1; CRBN; F2R; RBX1; FCGR3A; TNF; CYP1A2; RPL13; ABCC6; NFKB1; SPG7; XRCC5; ATP7A; CYP4B1; VEGFA; SULT1C4; PTGS2; HLA-B; FGF2; VWF; CUL4A; CHST3; MECOM; NAT2; HGF; ERCC1; CTLA4; SLC10A2; CYP2C19; ITGB2; CTNNB1; IL6R; GSTT1; SNORD68; PPARD 2024-07-24
Thioguanine N Y N N 1966 N DB00352 L01BB03 CHEMBL727 Acute Nonlymphocytic Leukemia; Nonlymphocytic Acute myeloid leukemia KDM4A; CPT1A; GDA; GATA2; LINC00251; GGH; HPGD; IGHMBP2; MGMT; NUDT15; PNPLA3; EHMT2; UGT1A1; NAT1; PAX8; GATA3; BMP7; TPMT; XDH; NFE2L2; IMPDH1; PRPS1; ACHE; IMPDH2; NT5C2; DOK5; MYC; IDH1; HBB; SLC28A3; AR; TPM3; ABCC4 2024-07-24
Thiotepa Y Y N N 1959 Y DB04572 L01AC01 CHEMBL671 Adenocarcinoma of the Ovaries; Breast Adenocarcinoma; Papillary transitional cell carcinoma of bladder; Malignant effusion TP53; HPGD; GMNN; ALDH1A1; CYP2B6; EHMT2; VDR; GSTP1; ALDH3A1; AR 2024-07-24
Tisagenlecleucel Y Y N N 2017 N DB13881 L01XX71 CHEMBL3301574 Refractory B-cell precursor acute lymphoblastic leukemia; Second or later relapsed B-cell precursor acute lymphoblastic leukemia MS4A1; CD19 2024-07-24
Tislelizumab Y N N China N 2023 N DB14922 L01FF09 CHEMBL4297840 Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma GM2A 2024-07-25
Tisotumab Vedotin N Y N N 2021 N DB16732 L01FX23 CHEMBL4297841 Recurrent or metastatic cervical cancer TUBB1; F3; TUBA1B; TUBB8; TUBA3E; TUBB2A; TUBB6; TUBB2B; TUBA4A; TUBB; TUBA1C; TUBB4B; TUBA3C; TUBB3; TUBA1A; TUBB4A 2024-07-24
Tivozanib Y Y N N 2017 N DB11800 L01EK03 CHEMBL1289494 Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3 2024-07-24
Topotecan Y Y N N 1996 Y DB01030 L01CE01 CHEMBL84 Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer DDO; PAX8; IDH1; ABCG2; AR; PLK1; TOP1; ALK; KMT2A; HIF1A; HBB; TSG101; ABCB1; AKT1; TYMS; RB1; TOP1MT; NFE2L2; MDM2; USP1; PTEN; TP53; PIK3CA; BDNF; MUC16 2024-07-24
Toremifene Y Y N N 1997 Y DB00539 L02BA02 CHEMBL1655 Desmoid Tumors; Metastatic Breast Cancer CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80 2024-07-24
Toripalimab Y Y N N 2023 N DB15043 L01FF13 CHEMBL4297843 Metastatic and Recurrent Nasopharyngeal Carcinoma GM2A 2024-10-30
Tovorafenib N Y N N 2024 N DB15266 CHEMBL3348923 Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation RAF1; BRAF; ARAF; EFNA2; ZHX2 2024-07-24
Trabectedin Y Y N N 2015 N DB05109 L01CX01 CHEMBL450449 Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2 2024-07-24
Trametinib Y Y N N 2013 N DB08911 L01EE01 CHEMBL2103875 Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7 2024-07-24
Trastuzumab Y Y N Y 1998 N DB00072 L01FD01 CHEMBL1201585 Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma ERBB2 2024-07-24
Trastuzumab Deruxtecan Y Y N N 2019 N DB14962 L01FD04 CHEMBL4297844 HER2 Positive Breast Cancers ESR1; TOP1; ESR2; ERBB2 2024-07-24
Trastuzumab Emtansine Y Y N N 2013 N DB05773 L01FD03 CHEMBL1743082 Refractory, metastatic Non small cell lung cancer ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8 2024-07-24
Trastuzumab, Hyaluronidase Y Y N N 1998 N DB00072 L01XC03 CHEMBL1201585 Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma ERBB2 2024-07-24
Tremelimumab Y Y N N 2022 N DB11771 L01FX20 CHEMBL2108658 Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC) CTLA4; MSH6; CD274; GLRB; PMS2; MLH1; ALK; EGFR; MSH2 2024-07-24
Tretinoin N Y Y N 1971 Y DB00755 D10AD01; L01XF01 CHEMBL38 FAB classification M3 Acute promyelocytic leukemia SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C 2024-07-25
Trifluridine, Tipiracil Y Y N N 1980 Y DB00432 L01BC59; S01AD02 CHEMBL1129 Metastatic Colorectal Cancer (MCRC) ERBB2; SLC29A1; TP53 2024-02-07
Triptorelin N Y Y N 2000 N DB06825 L02AE04 CHEMBL1201334 Advanced Prostate Cancer GNRHR; STS 2024-07-24
Trofosfamide N N Y N DB12902 L01AA07 CHEMBL462019 Non-Hodgkin's lymphoma CYP2B6 2024-02-07
Tucatinib Y Y N N 2020 N DB11652 L01EH03 CHEMBL3989868 Breast Cancer; Unresectable Breast Cancer ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4 2024-07-24
Umbralisib N Y N N 2021 N DB14989 L01EX25 CHEMBL3948730 B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL) PIK3CD; PIK3CG; ELF2; F7 2024-07-24
Valrubicin N Y N N 1998 Y DB00385 L01DB09 CHEMBL1096885 In situ BCG-refractory Bladder carcinoma TOP2A; AR 2024-02-07
Vandetanib Y Y N N 2011 N DB05294 L01EX04 CHEMBL24828 Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8 2024-07-24
Vemurafenib Y Y N N 2011 N DB08881 L01EC01 CHEMBL1229517 Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3 2024-07-24
Venetoclax Y Y N N 2016 N DB11581 L01XX52 CHEMBL3137309 Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1 2024-07-24
Vinblastine N Y Y Y 1965 Y DB00570 L01CA01 CHEMBL159 Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1 2024-07-24
Vincristine N Y Y Y 1965 Y DB00541 L01CA02 CHEMBL90555 Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA 2024-07-24
Vincristine Liposome N Y N N 2012 Y DB00541 L01CA02 CHEMBL501867 Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma TUBB6; TUBB3; TUBA3C; ALK; TUBB4A; GMNN; TUBB8; TUBB4B; TUBB2B; TUBA1A; TUBB1; TUBB; TUBA4A; HIF1A; TUBA3E; TUBA1C; NR0B1; TUBA1B; TUBB2A 2024-07-24
Vindesine N N Y N 1979 N DB00309 L01CA03 CHEMBL238071 Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant TUBB; ABCB1; TUBB1; CYP3A4 2024-07-24
Vinflunine Y N N N 2009 N DB11641 L01CA05 CHEMBL2110725 Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B 2024-07-24
Vinorelbine N Y Y Y 1994 Y DB00361 L01CA04 CHEMBL553025 Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8 2024-07-24
Vismodegib Y Y N N 2012 N DB08828 L01XJ01 CHEMBL473417 Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma SMO; PTCH1; SHH; ALOX12 2024-07-24
Vorasidenib N Y N N 2024 DB17097 L01XM04 CHEMBL4279047 Grade 2 astrocytoma or oligodendroglioma IDH1; IDH2; GRB2; GPX1P2 2024-11-28
Vorinostat N Y N N 2006 N DB02546 L01XH01 CHEMBL98 Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma TUBA1C; TUBA3D; IDH1; PAX8; TUBB4A; TUBB4B; GAS1; GAPDHP1; HDAC9; TUBB2A; TUBB8; HDAC6; BRAF; NR0B1; HDAC7; HDAC2; GART; HDAC8; GAPDHL17; HDAC11; HDAC4; GAS2; HDAC5; BIRC5; HDAC1; CFTR; TUBA3C; HDAC3; GDF2; GARS1; MYC; TP53; TUBA1A; TUBA3E; CHD4; MSTN; TUBB2B; UGT2B17; TUBA1B; TUBB6; TUBB1; LRRC32; BAP1; GMNN; TUBB3; ERBB2; FBXW7; NFE2L2; ACE; GNA11; HDAC10; TUBB; PTEN; RB1; TUBA4A 2024-07-24
Zanubrutinib Y Y N N 2019 N DB15035 L01EL03 CHEMBL3936761 Mantle Cell Lymphoma (MCL) TP53; BTK; EFNB2; MYD88 2024-07-24
Zolbetuximab Y Y N N 2024 DB15118 L01FX31 CHEMBL2109427 Locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma GRIN2A 2024-11-28